OBJECTIVE -To describe the costs of the Diabetes Prevention Program (DPP) interventions to prevent or delay type 2 diabetes.
T he Diabetes Prevention Program
(DPP) demonstrated that both medication and lifestyle interventions can delay or prevent progression from impaired glucose tolerance (IGT) to type 2 diabetes (1) . The DPP demonstrated that compared with the placebo intervention, the intensive lifestyle intervention reduced the incidence of type 2 diabetes by 58% and the metformin intervention reduced the incidence of type 2 diabetes by 31% over 2.8 years (1) .
The DPP enrolled 3,234 participants with IGT (fasting plasma glucose of 95-125 mg/dl and plasma glucose 2-h after a 75-g oral glucose load of 140 -199 mg/dl) who were at least 25 years of age and had a BMI Ն24 kg/m 2 (Ն22 kg/m 2 in AsianAmericans). Mean age of the participants was 51 years, and mean BMI was 34.0 kg/m 2 . Of the participants, 68% were women and 45% were members of minority groups.
The goals for the participants assigned to the intensive lifestyle intervention were to achieve and maintain a weight reduction of at least 7% of initial body weight through a healthy, lowcalorie, low-fat diet and physical activity of moderate intensity, such as brisk walking, for at least 150 min per week. A 16-lesson curriculum covering diet, exercise, and behavior modification was designed to help the participants achieve these goals. The curriculum, taught by case managers on a one-to-one basis during the first 24 weeks after enrollment, was flexible, culturally sensitive, and individualized. Subsequent individual sessions (usually monthly) and group sessions with the case managers were designed to reinforce the behavioral changes.
The medication interventions (metformin and placebo) were initiated at a dose of 850 mg taken orally once a day. At 1 month, the dose of metformin or placebo was increased to 850 mg twice daily, unless gastrointestinal symptoms warranted a longer titration period. The initiation of treatment with half a tablet was optional. Adherence to the treatment regimen was reinforced quarterly. The standard lifestyle recommendations for the medication groups were provided in the form of written information and in an annual 20-to 30-min individual session that emphasized the importance of a healthy lifestyle (1) .
In this report, we describe the costs associated with the primary prevention of type 2 diabetes in the DPP. Because the costs of new treatments may be barriers to their widespread implementation, a detailed and accurate description of costs should help health systems and policy makers to translate the results of the DPP into efficient clinical and public health practice. These data will also provide the basis for studies of the cost-effectiveness of the DPP interventions.
RESEARCH DESIGN AND METHODS -In this report, we describe the costs of the DPP interventions and the direct medical costs, direct nonmedical costs, and indirect costs of the lifestyle and metformin interventions compared with the placebo intervention. The closing date for data used in these analyses was 31 July 2001. In general, costs were calculated by applying standard unit costs to the resources used (2) . The unit costs used, and their sources, are summarized in the APPENDIX. We excluded the resources used and costs of the research component of the DPP from this analysis. The research component of the DPP included the resources used for recruitment of participants and for data collection and surveillance of complications and outcomes beyond those recommended for routine clinical practice. All costs were adjusted to year 2000 U.S. dollars using the consumer price index and the medical consumer price index (3) . The analysis was performed with a 3-year time horizon, the average length of follow-up within the DPP. In the tables, the total costs occasionally do not add up exactly because the numbers are rounded.
Direct medical costs
Direct medical costs represent expenditures for medical services and products and are usually paid by health systems (2) . These costs include the costs of hospitalization, outpatient care, laboratory tests, and medications. In estimating direct medical costs, we considered the costs of laboratory testing to identify persons with IGT, the costs of implementing and maintaining the DPP interventions, and the costs of care incurred or averted by the interventions that were captured by costs of medical care outside the DPP.
Direct nonmedical costs represent expenditures arising as a result of medical treatment of illness but not involving the purchase of medical services or products (2) . Since these costs do not represent health care expenditures, they are not usually paid by health systems. They do, however, represent "out-of-pocket" costs to patients and costs to society. In the DPP, direct nonmedical costs included the value of the time that participants spent traveling to and attending appointments, exercising, shopping, and cooking; the costs of exercise classes, exercise equipment, special foods, and food preparation items; and the costs of transportation to and from appointments.
Indirect costs are another cost to society that arise from illness-related morbidity and mortality (2) . Indirect costs from morbidity arise from being absent from work because of medical treatment, illness, or long-term disability. Indirect mortality costs arise from lost productivity due to premature death.
In these analyses, we have adopted two separate perspectives: the perspective of a large health system and the perspective of society. In the former analyses, adopting the perspective of a health system, we have considered the direct medical costs of the DPP interventions and the direct medical costs of care received outside the DPP. In the latter analysis, adopting the perspective of society, we have considered, in addition to direct medical costs, direct nonmedical costs and indirect costs.

Identification of individuals with IGT.
A variety of strategies were used to recruit subjects for the DPP. Costs were driven by the need to screen a large and diverse population over a short period of time (4) . Accordingly, we considered many of the costs of recruitment to have been research driven. We anticipate that in a nonresearch setting, health care providers will screen individuals at high risk for IGT as a part of ongoing medical care. Oral glucose tolerance tests (OGTTs) were performed to identify subjects eligible to participate in the DPP. We estimated the direct medical cost of identifying one subject with IGT as the number of OGTTs performed to successfully identify one randomized participant times the unit cost of the OGTT. The unit cost of the OGTT was based on Center for Medicare and Medicaid Services (CMS) reimbursement rates (APPENDIX). Interventions. To estimate the direct medical costs of the interventions, DPP staff from each of the 27 clinical centers completed a questionnaire (DPP Form D02, Resource Utilization and Cost of Intervention Questionnaire). This questionnaire described the types of personnel and the amount of their time involved in the various components of the interventions, the health education materials provided, the medications prescribed, and the laboratory tests performed. The frequency of encounters and calls was determined from the questionnaires, from case report forms, and from the manual of operations (5) . Median responses were used to estimate usual resource use. The daily medication cost was calculated based on the dose prescribed (0, 1, or 2 tablets per day) by study year and the unit cost per tablet (APPENDIX). To promote treatment adherence, each DPP clinical center received money for toolbox strategies ($1,167 per year per clinic for subjects in the placebo intervention, $1,167 per year per clinic for subjects in the metformin intervention, and $4,000 per year per clinic for subjects in the lifestyle intervention). DPP staff reported the proportion of these funds disbursed each year. Toolbox monies were used to purchase pill boxes and pill cutters for subjects in the metformin intervention group and to purchase exercise equipment that was loaned to subjects in the lifestyle intervention group. We considered toolbox monies spent to promote adherence to placebo treatment to be a research cost and did not include them in the cost of the placebo intervention.
Unit costs for personnel were calculated as the median salaries of personnel employed in the DPP with National Institutes of Health (NIH)-negotiated fringe benefit rates (APPENDIX). Overhead costs for DPP clinical centers were estimated as 69% of DPP personnel costs (6) . The costs of health education materials did not include development costs and were based on bulk reproduction or publishing rates. The costs of laboratory tests were based on CMS reimbursement rates (APPENDIX). Unit costs were based on the nationwide average reimbursements for hospital days, emergency room visits, urgent care and outpatient visits, and telephone consultations (APPENDIX). The cost of prescription medications was based on the median AWP of a prescription filled by Merck Medco and Co., Inc., a large U.S. pharmacy benefit manager (APPENDIX).
Direct nonmedical costs
To estimate direct nonmedical costs, we estimated participant time from the frequency and duration of encounters and calls as reported by the DPP staff (DPP Form D02, Resource Utilization and Cost of Intervention Questionnaire). We assumed that participants spent, on average, a total of 30 min traveling to and from DPP appointments and that travel time and time spent at DPP appointments had a value of $8 per hour, half of the average hourly wage in 2000 (APPENDIX). Participants also completed questionnaires to describe the time they spent exercising, shopping, and cooking; and to describe their enjoyment of leisure-time physical activity (DPP Form Q12, Economic Evaluation Questionnaire). Leisure time physical activity was valued according to whether participants "disliked," were "neutral," or "liked" leisure time physical activity (7). For those who disliked leisure time physical activity, their time was assigned a value of $8 per hour, half of the average hourly wage in 2000 (APPENDIX). For those who were neutral to it, their time was assigned a value of $4 per hour. For those who liked leisure time physical activity, their time was assigned a value of $0 per hour. Sensitivity analyses were performed to assess the impact of variation in the cost of leisure time physical activity on the cost of the interventions. In these analyses, leisure time physical activity was valued at $0 per hour, $8 per hour, and $16 per hour for all participants regardless of their exercise preferences. Participants were also asked to report the number of hours per week they spent shopping for and preparing food for themselves. The time that participants spent shopping for and preparing food was assigned a value of $4 per hour.
Questionnaires administered to participants (DPP Form Q12, Economic Evaluation Questionnaire) were also used to assess out-of-pocket purchases of health club and gym memberships, exercise classes, personal trainers, exercise equipment, commercial weight loss programs, cooking classes, and equipment for food preparation. Data were analyzed by treatment group. Services and products used by Ͼ5% of subjects were included in our analyses. We assumed that for persons purchasing specific services and products, items were purchased once during the 3-year period except for the following: exercise shoes (two pairs per year for lifestyle subjects, one pair per year for metformin and placebo subjects), health club 
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DIABETES CARE, VOLUME 26, NUMBER 1, JANUARY 2003memberships (1.5 years' membership per subject), exercise classes (1.5 years' attendance per subject), personal trainer (five visits per subject), commercial weightloss programs (1.5 years' attendance per subject), and cooking classes (three classes per subject). To depreciate durable equipment (defined as items that would last Ͼ3 years and had a purchase price of more than $100), we assumed that the equipment could be sold at 50% of the original purchase price after 3 years. Unit costs of services and products were estimated from the literature and are summarized in the APPENDIX. Participants were also asked about changes in the costs of food that they experienced since they entered the DPP (DPP Form Q12, Economic Evaluation Questionnaire). Specifically, they were asked about the costs of food at home, at fast-food restaurants, and at non-fastfood restaurants. For each source of food, participants were asked whether their expenditures "increased a lot," "increased some," "stayed the same," "decreased some," or "decreased a lot." For increased/ decreased "a lot," we assumed a 10% change; for increased/decreased "some," we assumed a 5% change; and for "stayed the same," we assumed 0% change. These percentage changes were then applied to U.S. per capita food expenditures for the year 2000: $1,633 for food at home, $675 for food from fast-food restaurants, and $755 for food from non-fast-food restaurants (APPENDIX). We estimated round-trip transportation costs to DPP appointments as $7 per visit (8). *Leisure-time physical activity was valued according to whether participants "disliked," were "neutral," or "liked" leisure-time physical activity. †We assumed that durable equipment initially valued at Ͼ$100 (see APPENDIX) retained 50% of its original purchase price after 3 years. Percent value stated in rounded numbers.
baseline evaluation and 19% of subjects had exercise stress tests. Care outside the DPP. There were no statistically significant differences in the incidence of serious adverse events or adverse events among the three intervention groups. To estimate the costs of either side effects associated with participation in the DPP interventions or improved health, we assessed the mean per capita number and cost of hospital days, emergency room visits, urgent care visits, outpatient visits, calls to providers, and prescription medications over 3 years within each intervention group and the per capita differences in costs over 3 years among the intervention groups (Table 4) . Reported resource utilization was lowest in five of six categories among the lifestyle participants. In four of six categories, resource utilization was lower in the metformin group than in the placebo group. Over 3 years, the per capita direct medical costs of care outside the DPP were $5,011 in the placebo group, $4,739 in the metformin group, and $4,579 in the lifestyle group. Per capita direct medical costs of care outside the DPP were $272 less for the metformin group compared with the placebo group and $432 less for the lifestyle group compared with the placebo group. These cost savings indicate that metformin and lifestyle subjects used fewer medical resources outside the DPP than subjects randomized to the placebo intervention. Direct nonmedical costs Participants randomized to the three intervention groups reported that they spent different amounts of time attending appointments, traveling to and from appointments, exercising, shopping, and cooking and that they received different levels of enjoyment from leisure-time physical activity. They also reported different out-of-pocket purchases of services and products related to physical activity and diet, different expenditures for food, and different transportation costs. Table 5 summarizes these per capita direct nonmedical costs over 3 years. Because metformin and lifestyle participants made more visits than placebo participants, they spent more time traveling to and from appointments and attending appointments. Although lifestyle participants reported spending substantially more time in leisure-time physical activities, they were more likely to report that they enjoyed the activities than were metformin or placebo participants. Indeed, 76% of lifestyle participants and only 63% of metformin and 65% of placebo participants reported that they enjoyed their leisure-time physical activities. Twenty percent of lifestyle, 33% of metformin, and 31% of placebo participants were neutral toward their leisure-time physical activities and 4% of each group disliked them. As a result, the cost of the time spent exercising (shown in Table 5 as adjusted exercise) was quite similar among the three intervention groups. When the cost of leisure-time physical activity was changed to $0 per hour, $8 per hour, and $16 per hour regardless of participants' exercise preferences, the costs in the lifestyle group were $0, $5,027, and $10,054; costs in the metformin group were $0, $3,564, and $7,128; and costs in the placebo group were $0, $3,734, and $7,467, respectively. Both metformin and lifestyle participants reported spending less time shopping and cooking than placebo participants. In general, lifestyle participants purchased more services and products related to physical activity and diet than did placebo participants. Interestingly, lifestyle participants reported that their food costs were slightly lower than those of placebo participants, because of the lower costs of food consumed away from home. Metformin participants purchased the same or slightly fewer services and products related to diet and physical activity than the placebo participants, and they had similar food costs. Over 3 years, per capita direct nonmedical costs were $9 less for metformin participants and $1,445 greater for lifestyle participants compared with placebo participants.
Indirect costs
Participants in the three intervention groups reported small differences in time lost from school, work, or usual activities as a result of DPP visits, illness, or injury. In general, subjects in the placebo and metformin groups reported more time lost than subjects in the lifestyle group. There were also small differences in survival among the intervention groups. Over the first 3 years of the DPP, there were 3 deaths (1.023 deaths/1,000 person-years) in the lifestyle intervention group, 6 deaths (2.029 deaths/1,000 person-years) in the metformin intervention group, and 5 deaths (1.689 deaths/1,000 person-years) in the placebo intervention group. Days lost from school, work, or usual activities as a result of death were fewest in the lifestyle group. Table 6 summarizes these per capita indirect costs over 3 years. Over 3 years, indirect costs were $230 greater for metformin participants and $174 less for lifestyle participants than for placebo participants.
CONCLUSIONS -In the DPP, both the metformin and lifestyle interventions were more expensive than the placebo intervention. In the metformin intervention, most of the additional cost relative to the placebo intervention was accounted for by the cost of metformin. In the lifestyle intervention, most of the additional cost relative to the placebo intervention was accounted for by staff time used for counseling and adherence monitoring. Although the lifestyle intervention cost ϳ37% more than the metformin intervention in year 1, the lifestyle intervention cost 12 and 7% less than the metformin intervention in years 2 and 3. Because the cost of the lifestyle intervention was greater than the cost of the metformin intervention in year 1 but less in subsequent years, the cost of the lifestyle intervention relative to the metformin intervention would decrease with follow-up beyond 3 years. To the extent that the cost of the metformin intervention can be reduced by using less expensive generic metformin and to the extent that the lifestyle intervention can be delivered with less staff time, the cost of the interventions could be substantially reduced.
The cost of identifying IGT and the cost of the interventions represented less than one-half of total direct medical costs for DPP participants over 3 years ($2,919/ $7,375 ϭ 40% in the lifestyle, and $2,681/$7,420 ϭ 36% in the metformin group). Direct medical costs also included the costs of medical care obtained outside the DPP. The latter was influenced by both adverse health events and improvements in health related to participation in the clinical trial. There were no statistically significant differences in the incidence of serious adverse events or adverse events among the three intervention groups in the DPP. To estimate the costs of both adverse events and improved health associated with participation in the Although not generally paid by health systems, direct nonmedical costs affect the individual and society. To fully assess the impact of direct nonmedical costs, we went to great lengths to describe the resources used and to estimate their costs. Not surprisingly, participants in the lifestyle intervention group spent more time traveling to appointments, attending appointments, and exercising, and they purchased more services and products related to physical activity and diet. While the lifestyle group spent substantially more time engaged in leisure time physical activity than either metformin or placebo participants, they reported greater enjoyment of these activities. Thus, the resulting direct nonmedical cost was negligible. Both metformin and lifestyle participants reported spending less time shopping and cooking than placebo participants. Lifestyle participants also reported lower food costs than metformin and placebo participants-largely as a result of decreased cost of food consumed at restaurants. Because of more frequent DPP visits, participation in the lifestyle intervention was associated with substantially greater transportation costs.
Compared to the placebo intervention group, the incremental direct nonmedical cost was $1,445 over 3 years. Over 60% of this incremental cost was related to greater participant time. In contrast, direct nonmedical costs were $9 less in the metformin intervention group than in the placebo intervention group.
When leisure-time physical activity was valued independently of the participants' exercise preference at $0, $8, or $16 per hour, the incremental direct nonmedical cost of the lifestyle intervention compared with the placebo intervention increased substantially and ranged from $1,469 to $4,056 over 3 years. In contrast, direct nonmedical costs decreased in the metformin intervention group compared with the placebo intervention group (Ϫ$12 Ϫ$352). Thus, the cost of the lifestyle intervention relative to the placebo intervention is sensitive to the value assigned to time spent exercising. We believe that the base analysis that reflects participants' exercise preferences is most reasonable, because individuals who enjoy exercise willingly spend their leisure time and personal resources for exercise.
Despite the greater frequency of lifestyle visits, the difference in indirect costs among intervention groups was small. The latter may reflect flexible scheduling arrangements that permit people to reduce time lost from work or usual activities. Compared with the placebo group, the indirect costs related to morbidity and mortality were lower in the lifestyle group but higher in the metformin group. Thus, compared with the placebo group, indirect costs were $174 less in the lifestyle group and $230 greater in the metformin group over 3 years. Table 7 summarizes the per capita costs of the metformin and lifestyle interventions relative to the placebo intervention over 3 years. From the perspective of a large health system, which would pay only direct medical costs, the cost of the metformin intervention relative to the placebo intervention was $2,191 over 3 years. From the perspective of society, which pays direct medical costs, direct nonmedical costs, and indirect costs, the per capita cost of the metformin intervention relative to the placebo intervention was $2,412 over 3 years. The per capita costs of the lifestyle intervention relative to the placebo intervention were $2,269 and $3,540 over 3 years from the perspective of a large health system and society, respectively.
The DPP demonstrated that both medication and lifestyle interventions can delay or prevent progression from IGT to type 2 diabetes (1). This analysis demonstrates that such preventive strategies are associated with modest incremental costs. From the perspective of a large health system, both the metformin and lifestyle interventions cost ϳ$750 per participant per year, or $2,250 per participant over 3 years. From a societal perspective, the incremental costs of both the metformin and lifestyle intervention are greater and the relative increase is greater in the lifestyle than the metformin intervention. This is not surprising in light of the greater direct nonmedical costs associated with the lifestyle intervention. Nevertheless, the incremental increases remain small. The costs of such prevention strategies must be balanced against the savings related to averted disease. It is likely that the cost of the metformin intervention will decrease substantially with the availability of less expensive generic formulations of metformin. It is also likely that the cost of the lifestyle intervention could be reduced by improving the efficiency of utilization of staff time by using group visits. Ultimate determination of the value of these interventions to health systems and society will require a formal assessment of costs relative to the health benefits achieved in the DPP. 
APPENDIX
